{"id":"https://genegraph.clinicalgenome.org/r/25ee84ff-efe0-47b1-884d-7d232d3de57dv2.0","type":"EvidenceStrengthAssertion","dc:description":"MYOZ2 was first reported in relation to hypertrophic cardiomyopathy (HCM) in humans in 2007 (Osio et al., PMID: 17347475). MYOZ2 encodes a protein which belongs to a family of sarcomeric proteins that bind to calcineurin and are important in calcineurin signaling. The MYOZ2 gene has been related with HCM in 7 probands across 4 publications. One missense variant with experimental evidence to support its pathogenicity was identified in a patient and was shown to segregate with 5 additional family members (Osio et al., 2007, PMID: 17347475). Five additional unique variants with little to no experimental evidence to support their pathogenicity were reported (Osio et al., 2007, PMID: 17347475; Posch et al., 2008, PMID: 18591919; Cecconi M, et al., 2016, PMID: 27600940). Another unique missense variant was identified in a proband who also harbored a variant in MYH7 and was excluded as causative (Guo et al., 2017, PMID: 28296734). The mechanism for disease is unknown.\n \nThe gene-disease relationship is supported by expression data in the heart (Frey N, et al., 2000, PMID: 11114196), a mouse model that exhibits features of hypertrophic cardiomyopathy including left ventricular hypertrophy and interstitial cardiac fibrosis (Ruggiero A, et al., 2013, PMID: 22987565), and protein interaction with ACTN2 (Frey N, et al., 2000, PMID: 11114196). In summary, the evidence to support the gene-disease association between MYOZ2 and HCM is disputed as there has been a lack of supportive evidence since the previous curation and the points were reduced due to the new SOP. More evidence is needed to either support or entirely refute the role MYOZ2 plays in this disease. This gene-disease pair was originally evaluated by the ClinGen Hypertrophic Cardiomyopathy Gene Curation Expert Panel on June 26th, 2017. It was reevaluated on October 27th, 2022. As a result of this reevaluation, the classification changed from limited to disputed.  \n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/25ee84ff-efe0-47b1-884d-7d232d3de57d","GCISnapshot":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:summaryChange"},{"id":"cg:expertPanelChange"},{"id":"cg:otherTextChange"},{"id":"cg:newEvidence"},{"id":"cg:classificationChange"},{"id":"cg:sopChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10104","date":"2022-10-27T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10104","date":"2022-12-14T17:28:15.598Z","role":"Publisher"}],"curationReasonDescription":"Upon expert review, the classification was changed to disputed due to the lack of new supporting evidence and the reduction in points from the previous curation. ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da3a4c38-bd9f-4d5d-bc3e-3b1e7dfe988d","type":"EvidenceLine","dc:description":"This proband has a missense variant, Lys12Asn. The variant is reported in 1/6118 Other alleles at a frequency of 0.0001635, with no homozygotes in gnomAD v2.1.1. This variant is scored 0 points because it is of uncertain significance in ClinVar and the proband also has a variant in MYBPC3 (c.1624G>C p.Glu542Gln). ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da3a4c38-bd9f-4d5d-bc3e-3b1e7dfe988d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27600940","allele":{"id":"https://genegraph.clinicalgenome.org/r/180003fc-43ae-4b31-904d-e504725084e5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.36A>C (p.Lys12Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA104969015"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b953c40b-e33c-4a05-8520-80289b0d7ce8","type":"EvidenceLine","dc:description":"Benign in ClinVar. Too common to be causative. ExAC frequency: African (0.1769), Overall (0.04434).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b953c40b-e33c-4a05-8520-80289b0d7ce8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18591919","allele":{"id":"https://genegraph.clinicalgenome.org/r/f9aa61f5-e897-4024-aa92-4905c2230911","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.459A>G (p.Glu153=)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/31786"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2f4866df-007b-41fd-a079-a5d0c0d4db3c","type":"EvidenceLine","dc:description":"Benign in ClinVar. Too common. ExAC frequency 0.00918 overall.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f4866df-007b-41fd-a079-a5d0c0d4db3c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18591919","allele":{"id":"https://genegraph.clinicalgenome.org/r/77dba686-8b60-4281-9890-afa07a9c9e9c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.237A>G (p.Ala79=)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/31788"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5459f2f0-2433-4b55-b2dd-0a808d495c61","type":"EvidenceLine","dc:description":"The allele frequency is too high for this variant to be considered causative. gnomAD: European (Finnish) 0.02188, Overall 0.00230. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5459f2f0-2433-4b55-b2dd-0a808d495c61_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17347475","allele":{"id":"https://genegraph.clinicalgenome.org/r/a27b0ca5-4a10-4aee-97c2-c5d95086496b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.738A>G (p.Ile246Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/30509"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1f4d4a0f-7159-48aa-8973-325b600dc471","type":"EvidenceLine","dc:description":"This variant was present in 16 family members, but did not present with phenotype when individuals had this variant alone; however, the variant did present with positive phenotype in individuals who also had a variant in MYH7 (CAID: CA011779). The study concluded that the MYOZ2-L169G mutation alone was not found to be pathogenic, but it did appear to play a modifying role in HCM.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f4d4a0f-7159-48aa-8973-325b600dc471_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28296734","allele":{"id":"https://genegraph.clinicalgenome.org/r/bb7c15fd-5829-4a69-8112-54068d5bd6a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.505A>C (p.Lys169Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16609625"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/24141897-d651-4582-b8ff-55139e95190e","type":"EvidenceLine","dc:description":"This proband has a missense variant, Leu163Ser. The variant is reported in 43/24948 African/African American alleles at a frequency of 0.001724, with no homozygotes in gnomAD v2.1.1. This variant is scored 0 points because there are conflicting interpretations of pathogenicity in ClinVar and the frequency is too high.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24141897-d651-4582-b8ff-55139e95190e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27600940","allele":{"id":"https://genegraph.clinicalgenome.org/r/68f55e70-989c-4615-a12d-db6ba0bdfb85","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.488T>C (p.Leu163Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA282614"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e3eba72-69d0-471a-9cdc-60de6138b623_proband_segregation","type":"FamilyCosegregation","dc:description":"All individuals with HCM phenotype and MYOZ2 variants also had MYH7 variants when genotyped. Individuals with MYOZ2 variants only did not present with phenotype. The study concluded that the MYOZ2-L169G mutation alone was not found to be pathogenic, but it did appear to play a modifying role in HCM.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28296734","rdfs:label":"Guo_Family","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/6e3eba72-69d0-471a-9cdc-60de6138b623","type":"Family","rdfs:label":"Guo_Family","member":{"id":"https://genegraph.clinicalgenome.org/r/b2dba015-9ae4-449b-9749-c671668c247b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28296734","rdfs:label":"Guo III:15","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":37,"allele":{"id":"https://genegraph.clinicalgenome.org/r/bb7c15fd-5829-4a69-8112-54068d5bd6a3"},"detectionMethod":"WGS of an immediate family member from each generation. Sanger sequencing of all family members ","firstTestingMethod":"Other","phenotypeFreeText":"Left atrial diameter=38mm, left ventricular end-diastolic diameter=52mm, interventricular septum thickness max=20mm, left ventricular posterior wall thickness max=8mm","phenotypes":["obo:HP_0001712","obo:HP_0001639","obo:HP_0031352"],"previousTesting":true,"previousTestingDescription":"Transthoracic echocardiography, LV wall thickness and LV dimensions were measured perpendicular to the long axis of the left ventricle by M-mode imaging and 2-dimensional echocardiography, pulsed-wave, continuous-wave, and color Doppler were used as necessary for accurate definitions of obstruction","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1f4d4a0f-7159-48aa-8973-325b600dc471_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":7,"phenotypes":["obo:HP_0001712","obo:HP_0001639"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b2dba015-9ae4-449b-9749-c671668c247b"}},{"id":"https://genegraph.clinicalgenome.org/r/b5521b62-6981-4120-af75-e76927964cb8_proband_segregation","type":"FamilyCosegregation","dc:description":"This family meets criteria for inclusion (4 or more affected individuals who have been genotyped; there are 6 affected genotyped individuals in this family).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17347475","rdfs:label":"Family 109","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/b5521b62-6981-4120-af75-e76927964cb8","type":"Family","rdfs:label":"Family 109","member":{"id":"https://genegraph.clinicalgenome.org/r/3b2f1066-4ed5-4ecc-b755-c8bea5614eb2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17347475","rdfs:label":"Osio_III-3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6cf5a424-820f-44a4-802b-496aa72da42a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016599.5(MYOZ2):c.142T>C (p.Ser48Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/30508"}},"detectionMethod":"Linkage analysis identified a critical region that includes 30 genes. All 6 exons and intron-exon boundaries of MYOZ2, the only gene encoding a sarcomeric protein within that critical region, were sequenced.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Heart failure, syncope, left ventricular hypertrophy (septal thickness 3.2 cm), atrial fibrillation, supraventricular tachycardia.","phenotypes":["obo:HP_0004755","obo:HP_0005110","obo:HP_0001712","obo:HP_0001279","obo:HP_0001635"],"previousTesting":true,"previousTestingDescription":"Negative for MYH7, MYBPC3, TNNC1, and TNNT2 by direct sequencing.  Locus-specific haplotyping to screen TNNI3, TPM1, ACTC1, TTN and MYOZ2.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b1395c35-e480-4614-aabf-9c184ccacc97_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17347475","allele":{"id":"https://genegraph.clinicalgenome.org/r/6cf5a424-820f-44a4-802b-496aa72da42a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0005110","obo:HP_0001712"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/3b2f1066-4ed5-4ecc-b755-c8bea5614eb2"},"publishedLodScore":2.03,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b1395c35-e480-4614-aabf-9c184ccacc97","type":"EvidenceLine","dc:description":"This proband has a missense variant, p.Ser48Pro, that is pathogenic/likely pathogenic in ClinVar, but is not listed in gnomAD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b1395c35-e480-4614-aabf-9c184ccacc97_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b1395c35-e480-4614-aabf-9c184ccacc97_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data in Ruggiero 2013 (PMID 22987565). Mice expressing p.Ser48Pro develop left ventricular hypertrophy and cardiac fibrosis.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/509c5b55-0d61-4744-a6b4-b44466019bb3","type":"EvidenceLine","dc:description":"Please see also, PMID: 24309898 (also found in NCBI gene). RNA-seq was performed of tissue samples from 95 human individuals representing 27 different tissues in order to determine tissue-specificity of all protein-coding genes. High specificity in the heart is shown.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8edc2d89-afe6-4ecd-9ce6-9659cae996bb","type":"Finding","dc:description":"Northern blots of RNA from human and mouse multiple tissues showed expression in heart and skeletal muscle in human, and heart in mouse.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11114196","rdfs:label":"MYOZ2 expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1b1431d0-1b17-43a0-a8b4-afa5f1596fe4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67316a53-aa3f-42a2-b5c0-d01cb7a5be31","type":"Finding","dc:description":"Calsarcin 1 interacts and colocalizes with the z-disk protein Î±-actinin, encoded by ACTN2, in vitro and in vivo and thereby tethers calcineurin to the sarcomere of cardiac and skeletal muscle. Calcineurin has been shown to have a profound influence on the properties of striated muscle cells, including cardiac muscle. ACTN2 has been previously implicated in intrinsic cardiomyopathy. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11114196","rdfs:label":"MYOZ2 and ACTN2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d74395ba-66ee-43c6-8d3c-c353bd8e5e82_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d04b838a-f4ab-40b7-80c3-446f98983b64","type":"EvidenceLine","dc:description":"Points reduced because p.I246M is a common variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d63aafdc-a6de-4626-a410-7c39ec40044b","type":"Finding","dc:description":"Mice expressing mutant MYOZ2 exhibit features of hypertrophic cardiomyopathy including left ventricular hypertrophy and interstitial cardiac fibrosis.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22987565","rdfs:label":"MYOZ2 mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Disputed","sequence":5447,"specifiedBy":"GeneValidityCriteria9","strengthScore":3.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/wSBNjl7F2wA","type":"GeneValidityProposition","disease":"obo:MONDO_0005045","gene":"hgnc:1330","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_d74395ba-66ee-43c6-8d3c-c353bd8e5e82-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}